Seer, Inc.

Good day. Thank you for standing by. Welcome to the SEER Inc. Third Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. Please be advised today's conference may be recorded. If you require any further assistance, please press star, then zero. I would now like to hand the conference over to your host today, Carrie Mendeville, Investor Relations. Please go ahead.

Thank you. Earlier today, SEER released financial results for the quarter ended September 30th, 2021. If you have not received this news release, or if you'd like to be added to the company's distribution list, please send an email to investor at seer.bio. Joining me today from SEER are Omid Farraqsad, Chairman, CEO, and Founder, Omido Sadan, President and Chief Operating Officer, and David Horn, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release here issued today. For a more complete list and description, please see the risk factors section on the company's quarterly report on Form 10-Q for the quarter ended June 30th, 2021 and in its other filings with the Securities and Exchange Commission. Except as required by law, SEER disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast November 9th, 2021. With that, I'd like to turn the call over to Amin.

Thanks, Carrie. We're continuing to make outstanding progress and I could not be more pleased with the momentum as we approach the close of 2021 and prepare for broad commercial release in early 2022. Coming into 2021, we were focused on four key areas. First, setting the pace for innovation in the proteomics space. Second, leveraging the unique capabilities of our differentiated solutions. Third, coupling exceptional customer experience with transformative products, and fourth, forming strategic relationships with key customers and partners. And of course, as always, and most importantly, we're focused on continuing to grow our incredibly talented team. Now, 10 months into the year, we have demonstrated tangible progress across all four areas on innovation, our team has continued to push the boundaries of our technology at the interface of nanotechnology, biology, and machine learning to deepen our access to the proteome and its variants. On our unique capabilities, the power of this technology is its ability to enable highly robust, deep, unbiased proteomics at scale. As we progress through limited release, we're seeing an increasing number of customers planning at scale studies of a thousand samples or more. This is fundamentally transformative as prior to SEER, the most deep unbiased plasma proteomics studies that were done were in the size range of tens of samples. With regards to the customer experience, the ProteoGraph has been performing exceptionally well in the hands of customers. customers are extremely pleased with the entire spectrum of the experience, from efficiency of stall and validation, to training, to ease of use, and quality of data that they're generating. We're really excited to see several abstracts being presented in the fall conferences. And notably, these data were generated within just a few months following access to the prototype for most of these customers. On strategic relationships, We're making strong progress with our commercial partnerships to streamline workflows, expand geographic footprint, and set up global centers of excellence. We're also expanding our supply chain partnerships to enforce our ability to support our growing customer base globally. And of course, finally, with our team, we have continued to build our organization and add talent across a number of critical funds, including operations and quality, product development and data, and our commercial team. We are well positioned to scale our business as we head into 2022 and broad release. Now, we continue to see a strong market response to their prototype product suite. Revenue for the third quarter was $2.2 million, with $1.6 million of product-related revenue reflecting the increase in the install base and usage of the Protograph product suite. Our funnel of prospective customers continues to expand and include a broad range of global customer types, including pharma. We added new limited release customers in the third quarter, and we are on track to meet our goals of high single-digit number of sites across key applications and markets. We are particularly pleased with the caliber and ambitions of these customers. Early data was submitted by customers to the American Society for Mass Spectrometry, or ASMS, conference, which was last week, demonstrating how uniquely this technology enables deep unbiased plasma proteomics at scale. We saw customers apply our technology in new ways for the first time. including novel methods such as TMT, novel analysis such as glycoproteomics, and novel insights generated from deep and unbiased detection of disease-related proteins. Collectively, this body of data demonstrates the power and flexibility of our technology to empower customers and open up this market. Throughout our first two phases of commercialization, has been extremely pleased with how our technology has performed in customer hands, including ease with which the system has been implemented, robustness of how the assay performs, and quality of data that is being generated. We have also developed close customer relationships, which will enhance our ability to rapidly deploy applications, accelerate market creation, and drive adoption as we head into broad release. And the feedback we're receiving indicates that customers are really quite pleased, whether they come from the proteomics, genomics, or the background. They have been able to get up to speed and get going very quickly with our automated assay that requires little hands-on time to provide an easy-to-use, rapid, and reproducible workflow. it is clear that our solution is positioned to enable deep unbiased proteomics at scale for the first time. The ability for our technology to rapidly expand the discovery of new content at the amino acid or peptide level is one of the most significant variables in opening up this market. We're also uniquely solving the sampling problem, surveying the entire dynamic range of the plasma proteome. In doing so, will not only enable discovery of novel content at an unprecedented rate, but will also enrich the value that the entire proteomics ecosystem can create. This will benefit mass spec providers, software providers, and others, which is why so many of these companies have begun to partner with us. As we expand our footprint globally with what is already a disruptive product, we're also pushing a next set of innovations to further expand the capabilities of the ProteoGraph product suite. We're continuing to expand our software feature sets, streamline data management across our workflow, and leverage the power of our nanoparticles to lay a roadmap into the future. We are committed to driving a continuous stream of new products and product enhancements that will set the pace for innovation in proteomics. There continues to be a growing enthusiasm and energy around our technology. We continue to make strong progress across all dimensions of our business as our performance this quarter demonstrates. We're rapidly laying the groundwork for broad release in 2022. I'm inspired by the progress of our customers, proud of the strides we're making with our technology, and grateful for the hard work that the SEER team is putting in every day. With that, I will now turn the call over to Amit for more detail on our commercial progress.